 |
VOOZH | about |
|
VOOZH | about |
*612585
Table of Contents
Alternative titles; symbols
HGNC Approved Gene Symbol: CLPTM1L
Cytogenetic location: 5p15.33 Genomic coordinates (GRCh38) : 5:1,317,752-1,345,099 (from NCBI)
Using differential display to identify genes involved in resistance to the anticancer drug cisplatin in ovarian cancer cell lines, followed by 5-prime RACE of the cisplatin-resistant cell line, Yamamoto et al. (2001) cloned CLPTM1L, which they called CRR9. The deduced 512-amino acid protein contains 5 putative transmembrane regions and shares 35% identity with CLPTM1 (604783).
Hartz (2009) mapped the CLPTM1L gene to chromosome 5p15.33 based on an alignment of the CLPTM1L sequence (GenBank AB045223) with the genomic sequence (NCBI36).
Using Northern blot analysis, Yamamoto et al. (2001) found that expression of CRR9 was upregulated in all cisplatin-resistant cell lines examined. Overexpression of CRR9 in a cisplatin-sensitive cell line resulted in apoptosis, whereas CRR9 overexpression had no effect on a cisplatin-resistant cell line. Yamamoto et al. (2001) concluded that CRR9 is not associated with cisplatin resistance but with cisplatin-induced apoptosis, and that cisplatin resistance is likely due to a signaling change downstream of CRR9.
For discussion of a possible association between variation in the CLPTM1L gene and lung cancer, see 612571.
Hartz, P. A. Personal Communication. Baltimore, Md. 2/6/2009.
Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., Ohtake, Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem. Biophys. Res. Commun. 280: 1148-1154, 2001. [PubMed: 11162647, related citations] [Full Text]
Alternative titles; symbols
HGNC Approved Gene Symbol: CLPTM1L
Cytogenetic location: 5p15.33 Genomic coordinates (GRCh38) : 5:1,317,752-1,345,099 (from NCBI)
Using differential display to identify genes involved in resistance to the anticancer drug cisplatin in ovarian cancer cell lines, followed by 5-prime RACE of the cisplatin-resistant cell line, Yamamoto et al. (2001) cloned CLPTM1L, which they called CRR9. The deduced 512-amino acid protein contains 5 putative transmembrane regions and shares 35% identity with CLPTM1 (604783).
Hartz (2009) mapped the CLPTM1L gene to chromosome 5p15.33 based on an alignment of the CLPTM1L sequence (GenBank AB045223) with the genomic sequence (NCBI36).
Using Northern blot analysis, Yamamoto et al. (2001) found that expression of CRR9 was upregulated in all cisplatin-resistant cell lines examined. Overexpression of CRR9 in a cisplatin-sensitive cell line resulted in apoptosis, whereas CRR9 overexpression had no effect on a cisplatin-resistant cell line. Yamamoto et al. (2001) concluded that CRR9 is not associated with cisplatin resistance but with cisplatin-induced apoptosis, and that cisplatin resistance is likely due to a signaling change downstream of CRR9.
For discussion of a possible association between variation in the CLPTM1L gene and lung cancer, see 612571.
Hartz, P. A. Personal Communication. Baltimore, Md. 2/6/2009.
Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., Ohtake, Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem. Biophys. Res. Commun. 280: 1148-1154, 2001. [PubMed: 11162647] [Full Text: https://doi.org/10.1006/bbrc.2001.4250]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM